. Extensive studies have demonstrated that ibrutinib effectively treats a variety of hematological malignancies [3] [4] [5] [6] [7] . Additionally, its efficacy against immune complex disease models where myeloid cells such as neutrophils, monocytes, macrophages and dendritic cells mediate chronic inflammation suggests that ibrutinib may also target myeloid cells 8 . Btk
is expressed in different cell types within the myeloid lineage such as dendritic cells (DCs) and macrophages 9, 10 . Further, Btk enhances innate immune responses, participates in TLR-4 mediated myeloid cell activation 9, [11] [12] [13] [14] and also enables DCs to regulate T cell proliferation and differentiation 9 . Although ibrutinib has been shown to have varied effects on B cells, T cells and NK cells 1, [5] [6] [7] [8] , its effect on myeloid cells is still incompletely understood. Since DCs play a critical role in initiating and directing protective T cell responses during cancer 15, 16 , we wanted to study how ibrutinib affects the activation of DCs and their ability to prime T cell responses. Therefore, we determined the impact of ibrutinib treatment on DC culture and subsequent T cell activation using an in vitro model of murine bone marrow derived dendritic cells.
RESULTS AND DISCUSSION

Ibrutinib treatment alters cytokine and nitric oxide responses in LPS-treated DCs
Ligands to Toll-like receptors (TLRs) are potent activators of DCs and are being evaluated as adjuvants for dendritic cell based cancer therapies 15 . Further, it is known that Btk participates in TLR signaling in myeloid cells including DCs [9] [10] [11] [12] [13] [14] . Hence, we studied how ibrutinib affects immune responses in TLR-activated DCs using lipopolysaccharide (LPS), a TLR-4 ligand, as an immunogen for our studies. We examined whether ibrutinib modulates cytokine and nitric oxide (NO) production in DCs upon LPS stimulation. We studied these responses at various time points after LPS stimulation and at different concentrations of ibrutinib. LPS/ibrutinib-treated DCs dampened TNF-α production compared to LPS/control-treated DCs (Fig. 1A) , while IL-12 production was comparable between both groups (Fig. 1C) . There was reduced NO production in LPS/ibrutinib-treated DCs at a later time point compared to LPS/controltreated DCs (Fig. 1B) . Additionally upon ibrutinib treatment there was higher induction of IL-18, an increase in IL-6 and TGF-β at earlier time points of LPS stimulation, and an increase in IL-10 at a later time point compared to controls ( Fig. 2A-D) . The differences for IL-6, IL-10, IL-18 and NO were observed to be greatest mostly at the higher concentration of ibrutinib ( Fig. 1 and Fig. 2 ). Taken together, our results indicate that ibrutinib decreases TNF-α and NO production, increases the expression of IL-6, IL-10, IL-18 and TGF-β and does not alter IL-12 production upon LPS stimulation ( Fig. 1 and . Enhanced IL-6 production has also been reported in LPS stimulated Btk Hence, it is possible that the increased production of IL-6 and TGF-β in ibrutinib-treated DCs ( Fig. 2A and 2D ) contributes to the reduction of MHC-II and CD86 expression in these cells.
Ibrutinib-treated DCs promote an IL-17 response upon culture with T cells
DC-derived cytokines such as IL-6, IL-18 and TGF-β are critical in initiating and directing IL-17 production by T cells 20 . Based on the cytokine profile generated upon ibrutinib treatment ( Fig. 1 and 2 ), we hypothesized that ibrutinib-treated DCs would promote an IL-17 response from T cells. We investigated this by using an in vitro antigen-specific DC:T cell co-culture model. T cells co-cultured with LPS/ibrutinibtreated DCs displayed higher proliferation rates compared to T cells co-cultured with LPS/control-treated DCs (Fig. 4A) . We also evaluated the production of T cell cytokines in the co-culture supernatants. LPS/ibrutinib-treated DCs enhanced the production of IL-17, but not IFN-γ or IL-13 compared to LPS/control-treated DCs (Fig. 4B-D) . We could not detect the presence of IL-4 in either treatment (data not shown).
The balance of cytokines and co-stimulatory molecules expressed by DCs determines the T-helper subset generated during T cell differentiation. The production of both IL-6
and TGF-β by DCs promotes IL-17 production by T cells. Further, IL-17 synthesis by T cells can also be mediated by other cytokines such as IL-18 20 , which we observed to be increased in LPS/ibrutinib-treated DCs (Fig. 2C) . Although CD80-CD86/CD28-CTLA4 mediated co-stimulation has been suggested by some researchers to suppress IL-17 production by T cells 23, 24 , our studies suggest that differential regulation of CD80 and . We propose that ibrutinib should be further explored for its use in DC-based therapies due to its ability to modulate DC function and enhance DC-mediated T cell responses in a TLR-dependent manner. Our results also reveal a new mode of action for ibrutinib on DCs besides its previously known effects on B cells, T cells and NK cells 1, [5] [6] [7] [8] . Hence, the effects of ibrutinib on DCs and other myeloid cell populations must be further elucidated, especially in diseases where ibrutinib is currently being employed for treatment.
MATERIALS AND METHODS
Mice strains
Female C57BL/6 (age 8-10 weeks) and OT-II TCR transgenic mice (age 8-10 weeks)
were purchased from Harlan and Jackson Laboratories respectively. All animals were housed in a pathogen-free animal facility in The Ohio State University in accordance with National Institutes of Health and institutional guidelines.
Cultivation and stimulation of bone marrow derived dendritic cells
Bone marrow derived DCs from C57BL/6 mice were cultivated as described previously 32, 33 . Briefly, bone marrow cells were isolated from femurs and tibias of mice, After 5 days, T cell proliferation was evaluated by flow cytometry and culture supernatants were harvested to determine the concentration of cytokines by ELISA.
Real-time PCR analysis
Total RNA from LPS-stimulated DCs was extracted by adding TRIzol reagent to cells were determined by extrapolation from the generated standard curve using Softmax Pro software (Molecular Devices LLC).
Nitric oxide assay
Culture supernatants of LPS-stimulated DCs were tested for the presence of nitric oxide as described previously 36 . Briefly, nitrite was measured in culture supernatants using
Griess Reagent (Sigma Aldrich) with sodium nitrite as the standard. Plates were read using a Spectramax M3 microplate reader (Molecular Devices LLC) at the absorbance of 570 nm. The concentrations of nitric oxide were determined by extrapolation of generated standard curves using Softmax Pro software (Molecular Devices LLC).
Flow cytometry
LPS-stimulated DCs were washed with 1X PBS, blocked using normal mouse serum and incubated with conjugated antibodies against various cell surface markers including 
Statistical analysis
All statistical analyses were done using Prism 5 (GraphPad Software). Student's unpaired t test was employed to determine statistical significance of values obtained.
The p values less than 0.05 were considered statistically significant.
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